PharmaTimes

JANUARY 15, 2024

Companies collaborate to launch walk-in pain clinic

98

98

pharmaphorum

NOVEMBER 2, 2022

Ben Hargreaves discovers how chronic pain could be a key area for digital therapeutics, as they offer non-addictive and effective relief from the condition. The struggle to manage pain for individuals has been one that goes back a long way in history, with one of the earliest recorded medical prescriptions being for opium.

Food and Drug Administration 128

Food and Drug Administration Food FDA Patients 128

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for Pfizer and Myovant Sciences ’ Myfembree (relugolix 40mg, estradiol 1mg and norethindrone acetate 0.5mg) to manage moderate-to-severe pain linked with endometriosis in pre-menopausal women.

Food and Drug Administration 75

Food and Drug Administration FDA Management Physicians 75

Pharmaceutical Technology

DECEMBER 11, 2023

The funding will advance Hoba’s lead candidate HB-086 to Phase I clinical trial for chemotherapy induced neuropathic pain.

Leads 59

Leads 59

MedCity News

JUNE 6, 2023

But while painful for many, it can also be a valuable tool for organizations and validate new ideas, build organizational resilience, build a culture of quantifying success, learn how to activate data, and actually improve clinical, organizational and innovation-related outcomes.

96

96

European Pharmaceutical Review

JULY 13, 2023

In many European countries physicians can now prescribe medical cannabis for an array of chronic health conditions, including chronic pain, mental health disorders and neurological conditions. Cannabis complications There are notable complexities to researching medical cannabis using a linear approach to clinical translation.

Medical 89

Medical Food and Drug Administration Pharmacology Medicine 89

European Pharmaceutical Review

SEPTEMBER 14, 2023

Clinical evidence for rimegepant The clinical trial evidence shows that rimegepant is more likely to reduce pain at two hours than a placebo treatment, according to NICE. This peptide is thought to be responsible for the severe pain associated with migraine attacks.

Medicine 102

Medicine Patients Pharmaceutical 102

European Pharmaceutical Review

NOVEMBER 28, 2023

The FDA’s approval of Ogsiveo is based on results from the Phase III DeFi clinical trial , which were published this year in the New England Journal of Medicine. According to the FDA, this clinical trial evaluated 142 adult patients with progressing desmoid tumours not suitable to surgery.

Food and Drug Administration 87

Food and Drug Administration Medicine FDA Food 87

European Pharmaceutical Review

JUNE 19, 2023

A novel oral ‘robotic pill’ demonstrated a high success rate of drug delivery , according to clinical trial data presented at the Endocrine Society ’s annual meeting (ENDO 2023). “We The intestines do not have pain response to needles, so the injection is painless,” Dhalla explained. What drug does RT-102 contain?

Safety 94

Safety Medical Medicine Patients 94

Legacy MEDSearch

DECEMBER 12, 2022

Theranica , a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, announced that Highmark Inc. ” Clinical studies have shown Nerivio to be as effective as standard of care pharmacological options for acute migraine treatment.

Side effects 98

Side effects Insurance FDA Pharmacology 98

Medgadget

JULY 12, 2023

The system is designed as an alternative to total knee replacement, and can help to reduce pain and discomfort for patients when performing daily activities, such as walking. The MISHA Knee System reduces the peak forces on painful knee joints during activities such as walking, running, or simply standing.

Patients 73

Patients FDA 73

Legacy MEDSearch

OCTOBER 25, 2023

Theranica , a neuromodulation therapeutics company, announced the publication of a comprehensive clinical study in Advances in Therapy examining the long-term utilization, clinical efficacy, and safety of Nerivio ® , a Remote Electrical Neuromodulation (REN) device for the treatment of migraine. As for clinical efficacy, 74.1%

Side effects 52

Side effects Recruitment Networking Management 52

MedCity News

SEPTEMBER 12, 2022

To address this trend, healthcare clinics should regularly meet to assess the patient experience at their practice as well as staff pain points that can be alleviated through automation technology.

Healthcare 98

Healthcare Healthcare Patients Leads 98

Pharmaceutical Technology

JUNE 21, 2023

Dexmedetomidine is a common non-opioid analgesic that activates alpha-2 receptors, which inhibits the release of noradrenaline and subsequent propagation of pain signals. Opioid-based medication remains the go-to option for pain management. However, the opioid epidemic in the US has catalysed a shift in focus to alternatives.

Food and Drug Administration 80

Food and Drug Administration Pharma FDA Food 80

Nixon Gwilt Law

NOVEMBER 17, 2022

As part of its ongoing effort to expand access to evidence-based treatments for acute and chronic pain and to improve the care experience for individuals suffering from pain, CMS introduced new CPT codes for Chronic Pain Management (“CPM”) services in the 2023 Medicare Physician Fee Schedule Final Rule (the “2023 MPFS”).

Physicians 52

Physicians Management Patients Medical 52

Legacy MEDSearch

NOVEMBER 6, 2023

a bioelectric technology company focused on alleviating chronic post-amputation pain and restoring quality of life. Neuros Medical’s Altius System incorporates the company’s patented platform technology, On-Demand Bioelectric Nerve Block, which patients initiate as needed for targeted pain relief. Trinity Capital Inc.

Medical 52

Medical Recruitment Management Leads 52

Pharmaceutical Technology

FEBRUARY 19, 2024

RM-191A is under clinical development by RR MedSciences and currently in Phase II for Neuropathic Pain (Neuralgia).

40

40

European Pharmaceutical Review

MARCH 26, 2024

” Moderna reveals optimistic data for influenza-COVID-19 vaccine A promising mRNA vaccine What the clinical data showed Findings from the NextCOVE Phase III pivotal trial showed that mRNA-1283 facilitated a higher immune response in patients against both the Omicron BA.4/BA.5

Safety 95

Safety Leads Patients Pharmaceutical 95

Pharmaceutical Technology

MAY 19, 2023

inhibitor, STC-004, as a non-opioid therapeutic for acute and chronic pain conditions. inhibitor for the treatment of acute and chronic pain with the goal of reducing opioid use and preventing opioid use disorders”, the award is a UG3/UH3 phase innovation awards co-operative agreement in two phases.

Leads 52

Leads Patients 52

Pharmaceutical Technology

FEBRUARY 7, 2024

Sufentanil citrate is under clinical development by Talphera and currently in Phase III for Post-Operative Pain.

40

40

Pharmaceutical Technology

JANUARY 4, 2024

(Acetaminophen + nefopam hydrochloride) is under clinical development by Aptys Pharmaceuticals and currently in Phase III for Somatic Pain.

Pharmaceutical 40

Pharmaceutical 40

Medgadget

NOVEMBER 7, 2022

Small electrical shocks are then sent through the entire heart, potentially causing discomfort and pain. Moreover, when electrical signals are sent to the heart, every cell receives the shock, often leading to pain and discomfort. “It affects the heart muscle as a whole.”

Leads 104

Leads Physicians Patients 104

Legacy MEDSearch

APRIL 11, 2023

The MISHA Knee System is indicated to treat people with medial knee OA who failed to find relief from non-surgical or surgical treatment, continue to experience pain that interferes with daily activities, and are ineligible for, or unwilling to undergo, joint replacement due to age or absence of advanced OA. “I’ve

Marketing 96

Marketing FDA Food and Drug Administration Specialization 96

Pharmaceutical Technology

MARCH 10, 2023

It is a third-generation, selective and structurally unique, small molecule CGRP receptor antagonist and is currently under clinical development with oral and intranasal formulations. Zavzpret is claimed to be the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray approved to treat migraine.

Food and Drug Administration 98

Food and Drug Administration FDA Food Safety 98

Pharmaceutical Technology

FEBRUARY 7, 2024

Siltuximab is under clinical development by Recordati and currently in Phase II for Pain.

40

40

Pharmaceutical Technology

FEBRUARY 24, 2023

ACD-440 is under clinical development by AlzeCure Pharma and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is administered via cutaneous route.

Pharma 40

Pharma Pharmaceutical Medical 40

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The most common adverse events were fatigue, injection site pain and chills.

Patients 101

Patients Pharmaceutical 101

European Pharmaceutical Review

NOVEMBER 1, 2023

CHMP also considered data from a non-clinical study in previously vaccinated adults showing that when Nuvaxovid was adapted to target another related strain, Omicron BA.5, are pain and tenderness at the injection site, tiredness, headache, muscle pain and feeling generally unwell, EMA said.

Side effects 101

Side effects Medicine Safety Marketing 101

Legacy MEDSearch

FEBRUARY 8, 2023

This allows providers to combine TargetCool with other needle-based procedures to minimize patient pain, bruising, inflammation and hematoma that may occur post-procedure. Through this, TargetCool is creating a new standard of care in cooling and opening the door to an array of new treatment possibilities. The post CoolHealth Enters U.S.

Management 98

Management Medical Marketing FDA 98

Pharmaceutical Technology

DECEMBER 20, 2023

Meloxicam fast acting is under clinical development by Viatris and currently in Phase II for Post-Operative Pain.

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

Meloxicam fast acting is under clinical development by Viatris and currently in Phase II for Post-Operative Pain.

40

40

pharmaphorum

OCTOBER 19, 2022

Meanwhile, the joint keynote address ‘Clinical trials sufficiency for DTx’ will be delivered by chief policy officer of the Digital Therapeutics Alliance Megan Coder and Hannes Klöpper, CEO of HelloBetter.

Networking 100

Networking Management Medical 100

European Pharmaceutical Review

AUGUST 11, 2023

Crizanlizumab is a once-a-month, humanised monoclonal antibody infusion, indicated for the prevention of recurrent vaso‑occlusive crises (pain crises) in sickle cell disease patients aged 16 years and above. Despite earlier approval comprehensive clinical data is generated post-approval.

Marketing 88

Marketing Food and Drug Administration Medicine FDA 88

pharmaphorum

SEPTEMBER 20, 2022

data from the phase 2 LILAC (Part A) clinical trial published this month shows that the experimental lupus therapy could reduce disease activity in the joints of patients, globally improving their condition. Sponsored by Biogen Inc., Litifilimab could offer a lifeline. There is currently no known cure for lupus.

Medicine 109

Medicine Leads Safety Medical 109

Pharmaceutical Technology

JULY 27, 2022

The application for the drug comprised data from a Phase I clinical trial in healthy subjects, a Phase I/II trial analysing ascending dose levels, the Phase III VALOR trial and an open-label extension (OLE) trial. A decision from the regulatory agency on approval for the drug is anticipated on 25 January next year. Furthermore, 6.7%

Food and Drug Administration 98

Food and Drug Administration FDA Food Safety 98

Legacy MEDSearch

OCTOBER 13, 2022

(NYSE: NVRO ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that it has received approval from the U.S. “HFX iQ is designed to improve the consistency of pain relief and is the only SCS system that truly personalizes care,” stated D.

FDA 52

FDA Food and Drug Administration Recruitment Pharmacology 52

European Pharmaceutical Review

FEBRUARY 21, 2023

As well as having potential in helping to treat conditions such as chronic pain, developments in the field show the compound could help treat a wider variety of conditions. Arthur Wakeley What data can you share about clinical trials for cannabis-based medicines?

Medicine 131

Medicine Manufacturing Specialization Pharmaceutical 131